The Cancer institute of New Jersey (CINJ) is a matrix style, basic, clinical and population research center under the auspices of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. The Director serves as Associate Dean for Oncology Programs and is responsible for integrating research at the medical school with the Robert Wood Johnson University Hospital, School of Public Health, and several schools and departments of Rutgers University. CINJ was awarded its first P30 Cancer Center Support Grant (P30 NCI 072720) on March 1, 1997. CINJ has a current membership of 155, whose peer reviewed, funded research projects, as defined by the CCSG guidelines, total more than $50 million in direct costs, nearly $15 million of which is from the NCI. The research base of CINJ is organized into eight programs: Breast Cancer Research; Cancer Pharmacology/Developmental Therapeutics; Carcinogenesis and Chemoprevention; Cytokines, Cytokine Signaling and Cancer; Molecular Mechanisms of Tumor Growth; Prostate; Population Science, and Transcriptional Regulation and Oncogenesis. This application requests support for the following: Administration; Data Safety and Monitoring; Developmental Funds; Planning and Evaluation; Program Leaders; Protocol Review and Monitoring System; Protocol Specific Research; and Senior Leadership. In addition, we are requesting funds for the following shared resources of CINJ: Analytical Cytometry/Image Analysis; Centralized Education and Training for Clinical Research Personnel; DNA Sequencing; Immunohistochemistry; Laboratory Support Services; Office of Human Resource Services; Research Pharmacy; Tissue Retrieval Service; Transcriptional Profiling; and Transgenic/Knock-out Mouse Service.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA072720-11S2
Application #
7499924
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1997-03-01
Project End
2010-02-28
Budget Start
2007-09-24
Budget End
2008-02-29
Support Year
11
Fiscal Year
2007
Total Cost
$127,296
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23
Zloza, Andrew (2018) Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer. J Immunother Cancer 6:3
CeliĆ -Terrassa, Toni; Bastian, Caleb; Liu, Daniel et al. (2018) Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat Commun 9:5005
George, Blessy; Joy, Melanie S; Aleksunes, Lauren M (2018) Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp Biol Med (Maywood) 243:272-282
Paratala, Bhavna S; Chung, Jon H; Williams, Casey B et al. (2018) RET rearrangements are actionable alterations in breast cancer. Nat Commun 9:4821
Jian-Yu E; Graber, Judith M; Lu, Shou-En et al. (2018) Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem 25:2595-2607
Moloughney, Joseph G; Vega-Cotto, Nicole M; Liu, Sharon et al. (2018) mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation. J Biol Chem 293:16464-16478
Zhu, Sining; Jin, Juan; Gokhale, Samantha et al. (2018) Genetic Alterations of TRAF Proteins in Human Cancers. Front Immunol 9:2111
Perekatt, Ansu O; Shah, Pooja P; Cheung, Shannon et al. (2018) SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Res 78:4878-4890

Showing the most recent 10 out of 775 publications